Related Experiment Video

Updated: May 25, 2026

Ex Vivo Infection of Live Tissue with Oncolytic Viruses
12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

Progress of oncolytic viruses in sarcomas

Christina K Lettieri1, Pooja Hingorani, E Anders Kolb

  • 1Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ 85016, USA. clettieri@phoenixchildrens.com

Expert Review of Anticancer Therapy
|February 10, 2012
PubMed

Insights

Oncolytic virotherapy shows promise for pediatric sarcomas, an aggressive cancer. Advances in viral engineering and understanding immune responses are improving treatment outcomes.

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • Pediatric sarcomas are aggressive cancers with poor response to current treatments.
  • Oncolytic virotherapy offers a promising new avenue for treating these challenging pediatric malignancies.
  • Recent clinical trials show encouraging results for oncolytic virus therapy in pediatric cancers.

Purpose of the Study:

  • To review the current state and future potential of oncolytic virotherapy for pediatric sarcomas.
  • To highlight advances in oncolytic virus engineering and their impact on efficacy.
  • To emphasize the importance of understanding immune responses in optimizing treatment.

Main Methods:

  • Review of current clinical trials and research in oncolytic virotherapy for pediatric sarcomas.
  • Discussion of genetic engineering strategies for enhancing oncolytic viruses.
  • Analysis of the role of antiviral and anti-tumor immune responses.

Main Results:

  • Oncolytic virotherapy is increasingly being investigated in pediatric malignancies, with five open clinical trials.
  • Genetic modifications enhance viral tumor cell infection, oncolysis, and synergy with other therapies.
  • Understanding immune responses is crucial for maximizing therapeutic benefits.

Conclusions:

  • Oncolytic virotherapy is a developing and encouraging treatment modality for pediatric sarcomas.
  • Continued research in viral engineering and immunology will refine and improve treatment efficacy.
  • Further investigation is needed to fully realize the potential of oncolytic viruses in pediatric oncology.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses06:13

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Published on: November 24, 2014

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...